Vancomycin pharmacokinetics in small, seriously ill infants.

Area of Science:

• Pharmacology
• Neonatal Medicine
• Pediatric Infectious Diseases

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive infections in infants.
• Infant physiology, particularly in premature neonates, significantly impacts drug pharmacokinetics.
• Understanding vancomycin's behavior in this population is essential for safe and effective therapy.

Purpose of the Study:

• To characterize the pharmacokinetics of vancomycin in a cohort of small infants.
• To investigate the influence of postconceptional age and other factors on vancomycin clearance and half-life.
• To provide data supporting individualized vancomycin dosing strategies in neonates and young infants.

Main Methods:

• Conducted 20 pharmacokinetic studies in 17 infants receiving vancomycin for documented infections.
• Analyzed data from infants stratified by postconceptional age (≤41 weeks and >43 weeks).
• Utilized linear regression analysis to determine relationships between pharmacokinetic parameters and patient characteristics.

Main Results:

• No significant differences in elimination rate, volume of distribution, or clearance were found between neonates and infants aged 4-8 weeks (≤41 weeks postconception).
• Infants ≤41 weeks postconception exhibited significantly lower vancomycin clearance and prolonged mean beta-half-life compared to older infants (>43 weeks postconception).
• Vancomycin clearance showed a direct linear relationship with postconceptional age; beta-half-life was influenced by weight, volume of distribution, and gestational age.

Conclusions:

• Significant interpatient variability in vancomycin pharmacokinetics exists in prematurely born infants.
• Postconceptional age is a key determinant of vancomycin clearance in this population.
• Individualized pharmacokinetic studies are recommended to guide vancomycin dosage and interval selection in infants, especially those born prematurely.